We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Massachusetts Enacts Biosimilar Substitution Law

Massachusetts Enacts Biosimilar Substitution Law

Signing Paper
July 1, 2014

Massachusetts has become the eighth state to pass a law enabling pharmacists to substitute a biosimilar for a branded biological product, earning praise from industry groups that believe such state laws are vital to biosimilar adoption.

The law, signed by Massachusetts Gov. Deval Patrick (D), enables pharmacists to fill a prescription using a biosimilar instead of a biological product. The biosimilar must be cleared by the FDA to be interchangeable with the prescribed product, according to the law.

Pharmacists also have the responsibility to notify the physician and patient of the substitution. In addition, a pharmacist cannot substitute a biosimilar if the physician explicitly requests otherwise, the law says.

The state substitution laws come as FDA continues to develop a regulatory pathway for determining whether a biosimilar is interchangeable with a biologic.

States play a major role in crafting policies on how a product can be substituted in place of a doctor’s prescription, the Biotechnology Industry Organization said. The law in Massachusetts “maintains incentives for innovation and promotes a competitive market for biologic therapies,” BIO noted.

The Generic Pharmaceutical Association also praised Massachusetts’ action, adding that it supports legislation that does not add burdens to current pharmacy practice.

Massachusetts was the second state to adopt biosimilar legislation in June. Delaware passed a law that includes some liability protections for pharmacists, and requires them to notify doctors when a substitution is made. The two states join Florida, North Dakota, Utah, Indiana, Oregon and Virginia to adopt biosimilar substitution laws.

While the agency continues to develop the approval pathway, it is releasing guidance to help manufacturers prepare for biosimilar submissions. Recent draft guidance details the relevant pharmacokinetic and pharmacodynamics data drugmakers need to use in clinical trials for determining biosimilarity to a biologic. The guidance is one of five that the agency plans to release this year on biosimilars. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Purple_Approved_Stamp.gif

    Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

  • Triple Vaccine, needles

    Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing